journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Therapeutic Patents

journal
https://www.readbyqxmd.com/read/29424255/the-therapeutic-potential-of-cetp-inhibitors-a-patent-review
#1
Xinran Wang, Wei Li, Lijuan Hao, Honglei Xie, Chenzhou Hao, Chunchi Liu, Wenyan Li, Xuqiong Xiong, Dongmei Zhao
Epidemiological studies have identified that high levels of low-density lipoprotein-cholesterol (LDL-C) and low levels of high-density lipoprotein-cholesterol (HDL-C) are two independent causes of cardiovascular disease (CVD). Statins, niacin and fibrate are used for the treatment of CVD. However, some defects are shown in the treatment process. Thus, there is a demand for better treatment strategies that confer preferable efficacy with fewer side effects. Cholesteryl ester transfer protein (CETP) promotes the movement of CEs from HDL to LDL and VLDL in exchange for triglycerides (TGs)...
February 9, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29421930/research-and-development-of-anti-alzheimer-s-disease-drugs-an-update-from-the-perspective-of-technology-flows
#2
Kunmeng Liu, Hui-Heng Lin, Rongbiao Pi, Shinghung Mak, Yifan Han, Yuanjia Hu
Today, over 20 million people suffer from Alzheimer's disease (AD) worldwide. AD has become a critical issue to human health, especially in aging societies, and therefore it is a research hotspot in the global scientific community. The technology flow method differs from traditional reviews generating an informative overview of the research and development (R&D) landscape in a specific technological area. We need such an updated method to get a general overview of the R&D of anti-AD drugs in light of the dramatic developments in this area in recent years...
February 8, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29411697/current-insights-into-anti-hiv-drug-discovery-and-development-a-review-of-recent-patent-literature-2014-2017
#3
Xiaofang Zuo, Zhipeng Huo, Dongwei Kang, Gaochan Wu, Zhongxia Zhou, Xinyong Liu, Peng Zhan
To deal with the rapid emergence of drug resistance challenges, together with the difficulty to eradicate the virus, off-target effects and significant cumulative drug toxicities, it is still imperative to develop next-generation anti-HIV agents with novel chemical classes or new mechanisms of action. Areas covered: We primarily focused on current strategies to discover novel anti-HIV agents. Moreover, examples of anti-HIV lead compounds were mainly selected from recently patented publications (reported between 2014 and 2017)...
February 7, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29411657/tips-for-reading-patents-a-concise-introduction-for-scientists
#4
Kate E Donald, Km Mohibul Kabir, William A Donald
No abstract text is available yet for this article.
February 7, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29368977/quinazoline-and-quinazolinone-as-important-medicinal-scaffoldes-a-comparative-patent-review-2011-2016
#5
Abdul Hameed, Mariya Al-Rashida, Maliha Uroos, Syed Abid Ali, Arshia, Marium Ishtiaq, Khalid Mohammed Khan
Quinazoline and quinazolinone scaffolds represent an important class of biologically active nitrogen heterocyclic compounds. A variety of marketed drugs are based on these moieties. A diverse range of molecules with quinazoline/quinazolinone moieties have been reported to exhibit broad spectrum of biological activities. Area covered: This review covers recent efforts in the synthesis and biological screening of quinazoline/quinazolinone based compounds from 2011-2016. Expert Opinion: Quinazoline and quinazolinones represent a diverse class of biologically active nitrogen heterocyclic compounds with immense therapeutic potential...
January 25, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29366356/therapeutic-bispecific-antibody-formats-a-patent-applications-review-1994-2017
#6
Marie Godar, Hans de Haard, Christophe Blanchetot, Jacobus Rasser
Bispecific antibodies have become increasingly of interest by enabling new therapeutic applications such as retargeting cellular immunity towards tumor cells. About 23 bispecific antibody platforms have therefore been developed, generating about 62 molecules which are currently being evaluated for potential treatment of a variety of indications, such as cancer and inflammatory diseases, among which three molecules were approved. This class of drugs will represent a multi-million-dollar market over the coming years...
January 25, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29338548/glycine-transporter-1-inhibitors-a-patent-review-2011-2016
#7
Christopher L Cioffi
Numerous research groups have developed GlyT-1 inhibitors in the pursuit of providing a novel antipsychotic treatment for schizophrenia. Despite multiple compounds advancing into clinical trials, a GlyT-1 inhibitor has yet to emerge to treat patients. However, the approach remains heavily investigated as it presents potential therapeutic utility for several other CNS and non-CNS-related indications. Areas covered: This review discusses various GlyT-1 inhibitor chemotypes identified and provides an overview of patent applications filed and published during the period of 2011-2016...
January 17, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29324067/mao-inhibitors-and-their-wider-applications-a-patent-review
#8
Simone Carradori, Daniela Secci, Jacques P Petzer
Monoamine oxidase (MAO) inhibitors, after the initial 'golden age', are currently used as third-line antidepressants (selective MAO-A inhibitors) or clinically enrolled as co-adjuvants for neurodegenerative diseases (selective MAO-B inhibitors). However, the research within this field is always increasing due to their pivotal role in modulating synaptic functions and monoamines metabolism. Areas covered: In this paper, MAO inhibitors (2015-2017) are disclosed ordering all the patents according to their chemical scaffold...
January 17, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29334795/progress-in-the-development-of-histamine-h3-receptor-antagonists-inverse-agonists-a-patent-review-2013-2017
#9
Dorota Łażewska, Katarzyna Kieć-Kononowicz
Since years, ligands blocking histamine H3 receptor (H3R) activity (antagonists/inverse agonists) are interesting targets in the search for new cures for CNS disorders. Intensive works done by academic and pharmaceutical company researchers have led to many potent and selective H3R antagonists/inverse agonists. Some of them have reached to clinical trials. Areas covered: Patent applications from January 2013 to September 2017 and the most important topics connected with H3R field are analysed. Espacenet, Patentscope, Pubmed, GoogleScholar or Cochrane Library online databases were principially used to collect all the materials...
January 15, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29334286/an-editorial-on-the-article-patents-in-the-diabetes-area-in-the-years-2008-2016
#10
Sigurd Lenzen
No abstract text is available yet for this article.
January 15, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29298119/secondary-patents-in-the-pharmaceutical-industry-missing-the-wood-for-the-trees
#11
Saritha Kiran, Mohan Kulkarni
Introduction The critics of the Innovator pharmaceutical industry allege that secondary patents are trivial modifications over the primary patent, which extend its term and delay the entry of the generics in the market place. The protagonists regard secondary patents a result of continuous research and development (R&D), which help them introduce and protect new, differentiated products. Areas covered The areas covered are Product life cycle management (PLCM), Drug approval process, Orange book (OB) listed patents, US patent data...
January 3, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29224409/intellectual-property-considerations-for-molecular-diagnostic-development-with-emphasis-on-companion-diagnostics
#12
Harry Glorikian, Richard Jeremy Warburg, Kelly Moore, Jennifer Malinowski
The development of molecular diagnostics is a complex endeavor, with multiple regulatory pathways to consider and numerous approaches to development and commercialization. Companion diagnostics, devices which are "essential for the safe and effective use of a corresponding drug or diagnostic product" (see U.S. Food & Drug Administration, In Vitro Diagnostics - Companion Diagnostics, U.S. Dept. of Health & Human Services(2016), available at https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407297...
December 9, 2017: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29210300/fak-inhibitors-in-cancer-a-patent-review
#13
Peng-Cheng Lv, Ai-Qin Jiang, Wei-Ming Zhang, Hai-Liang Zhu
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes at sites of cell adhesion to the extracellular matrix (ECM) and mediates signalling events downstream of integrin engagement of the ECM. FAK is known to regulate cell survival, proliferation and migration. Areas covered: FAK expression has also been shown to be up-regulated in many cancer types. Previous study also indicates that FAK-mediated signaling and functions are intrinsically involved in the progression of tumor aggressiveness, suggesting that FAK is a promising target for anticancer therapies...
December 6, 2017: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29431052/corrigendum
#14
(no author information available yet)
No abstract text is available yet for this article.
March 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29297703/cancer-breath-testing-a-patent-review
#15
K M Mohibul Kabir, William A Donald
Human breath can contain thousands of volatile organic compounds (VOCs) and semi-volatile compounds that are related to metabolism and other biochemical processes. The presence of cancer cells can affect the identity and abundances of chemicals in breath when compared to those in healthy control subjects, which can be used to indicate the likelihood of a patient having cancer. Recently, the chemical analysis of exhaled breath from patients has been shown to be promising for diagnosing many different types of cancers, including lung, breast, colon, head, neck, and prostate, along with pre-cancerous conditions (dysplasia)...
March 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29119843/statement-of-retraction
#16
(no author information available yet)
No abstract text is available yet for this article.
December 2017: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/28929814/what-s-new-in-the-diagnosis-of-pancreatic-cancer-a-patent-review-2011-present
#17
REVIEW
Houria Boulaiz, María C Ramos, Carmen Griñán-Lisón, Maria E García-Rubiño, Francisca Vicente, Juan Antonio Marchal
Pancreatic cancer (PC) is the fourth leading cause of cancer-related death in the US with a 5-year survival rate of about 5%. Most patients have advanced metastatic disease mainly due to the lack of an effective early detection, and an extremely poor prognosis. Advancing in the fight against PC requires developing novel observable biomarkers at preclinical stages for early detection. Areas covered: This manuscript is an overview of different PC diagnostic modalities and the latest innovations made to enhance early PC detection through the patents published from 2011 to 2017...
December 2017: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29171765/serine-protease-inhibitors-to-treat-inflammation-a-patent-review-2011-2016
#18
Chahrazade El Amiri, Feryel Soualmia
Introduction Inflammation is a physiological part of the complex biological response of tissues to counteract various harmful signals. This process involves diverse actors such as immune cells, blood vessels, and nerves as sources of mediators for inflammation control. Among them serine proteases are key elements in both physiological and pathological inflammation. Areas covered Serine protease inhibitors to treat inflammatory diseases are being actively investigated by various industrial and academic institutions...
November 24, 2017: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29168921/bauhinia-forficata-in-the-treatment-of-diabetes-mellitus-a-patent-review
#19
Bárbara Verônica Cardoso de Souza, Regilda Saraiva Dos Reis Moreira Araújo, Oskar Almeida Silva, Lucas Costa Faustino, Maria Fabrícia Beserra Gonçalves, Mirian Lima Dos Santos, Grasielly Rocha Souza, Lindalva Moura Rocha, Mônica Larissa Sousa Cardoso, Lívio César Cunha Nunes
Diabetes Mellitus has been considered an epidemic by the World Health Organization, with a high risk of morbidity and mortality. The treatment of this pathology consists in glycemic control, which can be done by oral hypoglycemic agents, insulin therapy, dietary guidance, regular physical activity, and psychosocial support. In addition, other adjuvant treatments are employed, such as phytotherapic, and one of the most used plants is Bauhinia forficata. Areas covered: in the current review, patents using Bauhinia forficata for the Diabetes Mellitus treatment have been analyzed...
November 23, 2017: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29166791/evaluation-of-wo2017098421-gsk-s-benzothiazine-compounds-as-cd73-inhibitor-filings
#20
Ya-Ping Gong, Ren-Zhong Wan, Zhao-Peng Liu
There are considerable interests in the development of novel small-molecule CD73 inhibitors for the treatment of cancers, autoimmune diseases, precancerous syndromes, and other diseases associated with CD73 activity. Areas covered: The application claims novel substituted benzothiadiazine derivatives as CD73 inhibitors for the treatment of cancer, precancerous syndromes, AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Many of the exemplified compounds have pIC50 values between 5 to 8...
November 22, 2017: Expert Opinion on Therapeutic Patents
journal
journal
32389
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"